Gabapentin Generics: Pfizer’s Greenstone Captures 23% Of Market
This article was originally published in The Pink Sheet Daily
Executive Summary
As of Oct. 12, Teva held a 45.5% generic gabapentin share based on sales to large purchasers while Alpharma held 23.5% and Greenstone 23%, Teva says in court filings. Teva’s customers include CVS and McKesson; Greenstone is selling to Cardinal, Caremark and Medco.
You may also be interested in...
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.